Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
Simple item page
Full item details
- dc.contributor.author
- Parham, Kate A.
- Saeedian, Nasrin
- Ninkov, Marina
- Richer, Connor G.
- Li, Yue
- Wu, Kunyu
- Rashu, Rasheduzzaman
- Barr, Stephen D.
- Arts, Eric J.
- Haeryfar, S.M. Mansour
- Kang, C. Yong
- Troyer, Ryan M.
- Troyer, Ryan M.
- dc.date.accessioned
- 2025-02-07T21:09:59Z
- dc.date.available
- 2025-02-07T21:09:59Z
- dc.date.issued
- 2022-07-19
- dc.description.abstract - en
- Recombinant vesicular stomatitis virus (rVSV) vaccines expressing Spike proteins of Wuhan, Beta and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses in mice. rVSV-Wuhan and rVSV-Delta vaccines and a rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live SARS-CoV-2 Wuhan (USAWA1), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting of rVSV-Wuhan with rVSV-Delta induced strong nAb responses against Delta and Omicron viruses, with rVSV-Trivalent vaccine consistently effective in inducing nAbs against all the SARS-CoV-2 variants tested. All vaccines, including rVSV-Beta, elicited a spike-specific immunodominant CD8+ T cell response. Collectively, rVSV vaccines targeting SARS-CoV-2 variants of concern may be considered in the global fight against COVID-19.
- dc.description.sponsorship
- Funding for this study was provided by CIHR of Canada and the Public Health Agency of Canada through a COVID-19 Immunity Taskforce grant (2020-VR2-173205) to RMT; a grant from CIHR (COV-440388) to SDB, RMT, EJA, SMMH, and CYK; a CoVaRR-Net Rapid Response Research Grant to SDB; and from Sumagen Canada to CYK.
- dc.identifier.doi
- https://doi.org/10.1101/2022.07.19.500626
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3413
- dc.language.iso
- en
- dc.publisher - en
- bioRxiv
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.openaccesslevel - en
- Green
- dc.rights.openaccesslevel - fr
- Vert
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.title - en
- Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
- dc.type - en
- Article
- dc.type - fr
- Article
- local.pagination
- 1-29
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: parham-monovalent-trivalent-vsv-based-covid-19-vaccines.pdf
Size: 1.22 MB
Format: PDF
Collection(s)